Search alternatives:
significant strain » significant main (Expand Search), significant constraints (Expand Search), significant burden (Expand Search)
point decrease » point increase (Expand Search)
mean decrease » a decrease (Expand Search)
strain based » strains based (Expand Search), trait based (Expand Search), brain based (Expand Search)
significant strain » significant main (Expand Search), significant constraints (Expand Search), significant burden (Expand Search)
point decrease » point increase (Expand Search)
mean decrease » a decrease (Expand Search)
strain based » strains based (Expand Search), trait based (Expand Search), brain based (Expand Search)
-
1
-
2
-
3
-
4
-
5
-
6
Mean and standard error of the mean for force capability according to anchor point level change.
Published 2022Subjects: -
7
Homozygous deletion of <i>ERG251</i> leads to the decreased ergosterol accumulation in the absence of FLC and decreased production of toxic dienol in the presence of FLC.
Published 2024“…</b> Abundance of sterols in tested strains from Fig 6B. Values are mean ± SEM calculated from three biological replicates. …”
-
8
-
9
Change in the levels of parental stressors or rewards between time point 1 and time point 2.
Published 2022Subjects: -
10
-
11
Spatial information is significantly decreased in dCA1 and vCA1 in APP/PS1 mice.
Published 2024“…(B) In dCA1, spatial information was decreased in APP/PS1 mice relative to C57BL/6 controls (mean ± std: C57BL/6 = 0.132 ± 0.048, APP/PS1 = 0.128 ± 0.051, p < 0.005, two-sided Wilcoxon rank-sum test, n<sub>C57BL/6</sub> = 305 units from 5 recording sessions, n<sub>APP/PS1</sub> = 180 units from 4 recording sessions). …”
-
12
-
13
-
14
-
15
Genes significantly affected by deletion of <i>ryfA</i>.
Published 2021“…(<b>B</b>) Genes classified in different categories based on log2 fold-change difference. Genes upregulated (yellow rectangles) and downregulated (blue rectangles) by at least 1.7-fold were considered significant with P < 0.05. …”
-
16
-
17
Summary of post-treatment disease course measures from MDMA-AT publications.
Published 2025Subjects: -
18
-
19
Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications.
Published 2025Subjects: -
20